Follow-on Offering

Healthcare
Follow-on Offering

Summary

Baird served as co-manager on this offering

About

Natera, Inc. (“Natera” or the “Company”) (NASDAQ-GS:NTRA) recently completed an underwritten public offering of 4,791,665 shares of its common stock at a price to the public of $60.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 624,999 shares of common stock. The gross proceeds to Natera from the offering are expected to be approximately $287.5 million before deducting the underwriting discounts and commissions.

Natera is a pioneer and global leader in cell-free DNA testing. The mission of the Company is to change the management of disease worldwide with a focus on women’s health, oncology, and organ health. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The Company offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. Natera, Inc. is headquartered in San Carlos, California.
CONTACT US TO LEARN MORE
Healthcare
Follow-on Offering
Date
September 2020
Company
Natera, Inc.
Transaction
M&A
Sectors
Healthcare
Target Location
North America

Share